Possible XXXX -induced @entity137 .

@entity1 @entity2544 @entity137 @entity2176 @entity4688 @entity11682 @entity3371 @entity1483 @entity272 @entity5505 @entity1482 @entity616
OBJECTIVE: To report a case of @entity137 ( @entity137 ) possibly induced by @entity3371 . CASE SUMMARY: An 11-week-old @entity1 was referred to our hospital for tetrology of fallot surgical repair, performed on admission day 2. On day 3, the @entity1 developed third-degree @entity616 , necessitating pacemaker connection and oral @entity2544 3 mg/kg 3 times daily. @entity3371 1 mg orally twice daily, intravenous @entity1483 7 mg every 12 hours, and oral @entity1482 7 mg twice daily were started. On day 5, the @entity1 developed scaling @entity272 . On day 7, his temperature spiked to 37.8 degrees C, and pus discharge from the pacing wire site was noticed. Intravenous @entity2176 80 mg 3 times daily and intravenous @entity5505 200 mg 3 times daily were initiated. On the same day, @entity3371 was discontinued because we suspected that it had induced the skin reaction. On day 15, the @entity1 's skin problem progressed. The dermatologist diagnosed partial @entity137 . On that day, @entity2544 and @entity1483 were also discontinued. On day 16, the @entity1 still had some blisters, but the skin started to show signs of healing, until complete healing occurred on day 22. The @entity1 was discharged on oral medications: @entity1483 7 mg twice daily, @entity1482 7 mg twice daily, and @entity4688 0.1 mg twice daily. Three weeks later, he was followed up. No recurrences were observed. CONCLUSIONS: This case suggests @entity3371 induces @entity137 when combined with other @entity11682 medications. An objective causality assessment revealed that the adverse drug event was possible. Although it is a rare complication, healthcare providers should be familiar with its potential to occur and take appropriate treatment and prevention measures.
